Demis Hassabis

On August 5, 2026, Demis Hassabis did something few technology chief executives ever do: he handed his own company away. The Nobel laureate gave up day-to-day operational leadership of Google DeepMind, moving himself to Chair of Google DeepMind and Chief Scientist of Alphabet while keeping the CEO seat at Isomorphic Labs, his AI drug-discovery company. The stated reason was the mission that has organized his entire career. “I’ve been working towards AGI my whole life and now, like many of you, I feel it is close at hand,” he wrote in a note to staff, adding: “I’ve always believed the No.1 application of AI should be to improve human health. It’s time for AI to prove its unequivocal value to the world, and what better way to demonstrate that than to help finally cure diseases like cancer.” (9to5Google)

The restructure was announced by Alphabet CEO Sundar Pichai. Day-to-day leadership passed to Koray Kavukcuoglu, Google DeepMind’s chief technology officer, who became senior vice president reporting to Pichai and took charge of Gemini model development, frontier AI research, and the Gemini app and developer teams. Pichai noted Kavukcuoglu’s 13 years at DeepMind — he started its deep learning team and led breakthroughs including WaveNet and DQN — while Hassabis, who called Kavukcuoglu one of the world’s foremost AI experts, said he would keep working closely with Pichai “on strategic and global AGI matters” and advise the DeepMind leads. (9to5Google)

The same day brought a second signal that the old guard was moving: Jeff Dean, Google’s longtime AI chief, announced he was leaving after 27 years to launch an independent public benefit corporation called Discovery Loop, focused on accelerating discoveries in machine learning, science, and engineering — with Gemini co-lead Oriol Vinyals going with him and Google joining as a founding investor and Cloud partner. (9to5Google)

The $2.1 billion bet on AI-designed drugs

The other half of Hassabis’s 2026 story is Isomorphic Labs, the AI-first drug design company he founded in London in 2021. On May 12, 2026, it closed a $2.1 billion Series B — among the largest private raises ever in AI drug discovery — led by Thrive Capital, with participation from Alphabet, GV, Abu Dhabi’s MGX, Singapore’s Temasek, CapitalG, and the UK Sovereign AI Fund. The money is aimed at scaling IsoDDE, the company’s unified AI drug-design engine, and pushing its pipeline of therapeutic programs toward clinical trials; the company already counts Novartis, Eli Lilly, and Johnson & Johnson as strategic partners. (The Decoder)

Hassabis frames the venture as the culmination of everything before it. “As you’ve heard me say many times, I’ve always believed the No.1 application of AI should be to improve human health,” he said in his August staff note, and the company’s stated mission is “to solve all disease.” The August handover makes the logic legible: rather than running the frontier-model machine day to day, Hassabis is now spending his working life on the science seat — the drug company and the AGI strategy. (9to5Google; The Decoder)

The Nobel: solving the 50-year problem

The prize that made all of this possible came on October 9, 2024, when the Royal Swedish Academy of Sciences awarded half of the Nobel Prize in Chemistry jointly to Demis Hassabis and John Jumper “for protein structure prediction,” with the other half going to David Baker “for computational protein design.” In 2020, Hassabis and Jumper had presented AlphaFold2, an AI model that predicts a protein’s three-dimensional structure from its amino acid sequence — cracking a problem researchers had chased since the 1970s. With its help, they predicted the structures of virtually all of the 200 million proteins researchers have identified, and AlphaFold2 has since been used by more than two million people from 190 countries. “The Nobel Prize in Chemistry 2024 is about proteins, life’s ingenious chemical tools,” the Academy wrote, noting that among its scientific applications, researchers can now better understand antibiotic resistance and create images of enzymes that can decompose plastic. (NobelPrize.org)

From the chessboard to DeepMind

Hassabis was born in London on July 27, 1976, and was a chess prodigy, reaching master status as a teenager. At 17 he joined the British video-game developer Bullfrog Productions, where he worked as a designer on the science-fiction game Syndicate and served as lead programmer of Theme Park, released in 1994 — a hit that won the industry’s Golden Joystick Award. He studied computer science at Cambridge, earning a double first-class honours degree, and later gained a PhD in cognitive neuroscience from University College London. (TechCrunch; AI Magazine)

In 2010 he founded DeepMind Technologies in London with Shane Legg and Mustafa Suleyman, teaching AI to play old games from the 1970s and 1980s with the goal of building general-purpose AI. In early 2014 Google acquired the company for about $500 million, and DeepMind established an AI ethics board alongside the deal. The breakthroughs followed in sequence: in 2015 AlphaGo beat European Go champion Fan Hui — the first time an AI defeated a professional Go player — and the company later defeated the world champion at the strategy board game; in 2016 DeepMind became a founding member of the Partnership on AI; and AlphaFold’s protein-structure predictions, published in partnership with the European Molecular Biology Laboratory, were made freely available to the scientific community. In April 2023, DeepMind merged with Google’s Brain team to form Google DeepMind. (AI Magazine; TechCrunch)

The rise was not without friction. DeepMind courted controversy over data-sharing deals with the United Kingdom’s National Health Service, and Hassabis has balanced his optimism about AI with public caution — in March 2024 he was knighted for “services to artificial intelligence,” seven years after receiving a CBE for “services to science and technology,” a progression TechCrunch noted as telling: the knighthood named the field that had exploded into the mainstream after ChatGPT. (TechCrunch)

The Time cover and the biography

In December 2025, Time named the “Architects of AI” its Person of the Year, and Hassabis shared the cover with seven fellow AI leaders: Mark Zuckerberg, Lisa Su, Elon Musk, Jensen Huang, Sam Altman, Dario Amodei, and Fei-Fei Li. One of the issue’s two covers was an illustration paying homage to the famous 1932 photograph “Lunch atop a Skyscraper,” taken during the construction of Rockefeller Center; the other visualized the AI revolution as a construction site shaped like the letters “AI.” Time’s editor-in-chief warned that “every advancement comes with a cost,” pointing to resource consumption, job displacement, and concentrated corporate power — the darker side of the AI boom the honorees built. (The Asia Business Daily)

A few months later, Hassabis became the subject of a full-scale biography: Sebastian Mallaby’s The Infinity Machine: Demis Hassabis, DeepMind, and the Quest for Superintelligence (Penguin Allen Lane, March 2026). Reviewing it, the Hindustan Times recounts the fall of 2013, when Hassabis struggled to persuade investors that DeepMind would change the world — “I was fed up with scrambling around, trying to justify what I knew was the biggest thing of all time,” the book quotes him recalling. “I just thought, look, I’ll go to Google. I’ll get a shitload of computers and then I’ll solve intelligence.” The book traces him from a working-class North London family — a Chinese Singaporean mother and a Greek Cypriot father — through chess, games, Cambridge, and neuroscience to the leadership of the most consequential AI effort of the decade. (Hindustan Times)

What this profile does not claim

This profile does not state a single definitive price for Google’s 2014 acquisition of DeepMind — published figures range from $400 million to $650 million, and this profile uses the roughly-$500-million figure from two fully-read sources. It does not claim that any AI-designed Isomorphic Labs drug has entered clinical trials, or repeat lower-tier reports about trial timing or AGI arrival dates, since neither was confirmed by a fully-read source. It does not treat “Gemini 4” as a shipped product — the name appears only as a mention in Hassabis’s August 2026 staff note. And it does not repeat personal-life details (family, habits, pastimes) seen only in lower-tier biographical summaries, which this profile’s sourcing bar did not clear.